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Abstract
The complex multifactorial nature of AD pathogenesis has been highlighted by evidence implicating additional neurodegener-
ative mechanisms, beyond that of amyloid-β (Aβ) and tau. To provide insight into cause and effect, we here investigated the
temporal profile and associations of pathological changes in synaptic, endoplasmic reticulum (ER) stress and neuro-
inflammatory markers. Quantifications were established via immunoblot and immunohistochemistry protocols in post-mortem
lateral temporal cortex (n = 46). All measures were assessed according to diagnosis (non-AD vs. AD), neuropathological severity
(low (Braak ≤ 2) vs. moderate (3–4) vs. severe (≥ 5)) and individual Braak stage, and were correlated with Aβ and tau pathology
and cognitive scores. Postsynaptic PSD-95, but not presynaptic synaptophysin, was decreased in AD cases and demonstrated a
progressive decline across disease severity and Braak stage, yet not with cognitive scores. Of all investigated ER stress markers,
only phospho-protein kinase RNA-like ER kinase (p-PERK) correlated with Braak stage and was increased in diagnosed AD
cases. A similar relationship was observed for the astrocytic glial fibrillary acidic protein (GFAP); however, the associated
aquaporin 4 and microglial Iba1 remained unchanged. Pathological alterations in these markers preferentially correlated with
measures of tau over those related to Aβ. Notably, GFAP also correlated strongly with Aβ markers and with all assessments of
cognition. Lateral temporal cortex-associated synaptic, ER stress and neuro-inflammatory pathologies are here determined as late
occurrences in AD progression, largely associated with tau pathology. Moreover, GFAP emerged as the most robust indicator of
disease progression, tau/Aβ pathology, and cognitive impairment.
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Introduction
Alzheimer’s disease (AD), the most common cause of demen-
tia, is characterised by the accumulation of extracellular
amyloid-β (Aβ) containing plaques and intracellular neurofi-
brillary tangles (NFTs) composed of hyper-phosphorylated
tau. These hallmark features have largely been the focus of
AD research; for decades, the ‘amyloid cascade hypothesis’
[1] remained the foremost pathogenic concept in the field and
has since been revised to incorporate a role for earlier occur-
ring soluble species, which appear to hold more disease rele-
vance [2–4].
Attempts at effective pharmacological interventions have
thus far focussed on addressing the development of Aβ, and
more recently tau, pathology. However, after consistent fail-
ures in clinical trials, we are still without a disease-modifying
agent [5]. This has called into question the validity of current
hypotheses and our conceptual understanding of disease
aetiology. Certainly, the sequential spread of tau and Aβ
across brain regions exemplifies inherent differences of these
key pathological markers. For instance, cortical tau pathology
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starts in the entorhinal cortex (EC) and then spreads to the
hippocampus and lateral temporal lobes before reaching the
remaining areas of the neocortex [6]. In contrast, Aβ plaques
are first observed in the neocortex and reach the hippocampus
and EC in later stages [7], potentially depositing first in the
inferior temporal gyrus or orbitofrontal cortices [8, 9].
Furthermore, the separation between Aβ and tau is evident
in their correlative strength with disease status and/or cogni-
tive decline. Despite the genetic association of Aβwith AD, it
is tau pathology, genetically linked to frontotemporal lobar
degeneration (FTLD), which is the more robust indicator of
disease progression and cognitive decline [2, 3, 10].
Alongside the apparent ‘hallmark’ pathologies, several addi-
tional tissue alterations are also apparent and assumed to con-
tribute to either onset or progression of degenerative processes
[11]. Indeed, ageing itself and also numerous homeostatic
pathways have been linked to neurodegeneration, including
those associated with oxidative stress, inflammation, vascular
and metabolic dysfunction [12].
Here, we focussed on putative disease-relevant pathways
associated with synaptic pathology, neuro-inflammation and
endoplasmic reticulum (ER) stress (see [13–15] for review).
Synaptic loss, thought to occur early in the disease process,
may hold stronger functional relevance than the hallmark pa-
thologies and may precede neuronal degeneration [16, 17].
Indeed, a synaptic loss of 20–40% in the hippocampal region
has been reported in early AD [18, 19].
Similar to the loss of synapses, evidence for ER stress in the
form of the unfolded protein response (UPR) as signalled by
activation of protein kinase RNA-like ER kinase (PERK),
inositol-requiring enzyme 1α (IRE1α) and activating tran-
scription factor 6 (ATF6), has also been reported in the early
stages of AD [20–22] and associated animal models [23–25].
Early activation of the UPR appears most prominent in the
hippocampus [26, 27]. Downstream from PERK, the phos-
phorylation of eukaryotic initiation factor 2α (p-eIF2α) is
considered a major output of the UPR associated with the
inhibition of protein translation leading to impaired synaptic
plasticity, learning and memory and, thus, may connect the
UPR with synaptic deficits [23, 28, 29].
Associated with both synaptic loss [30] and ER stress [31],
aberrant central nervous system inflammation has also been
readily proposed as a contributing factor to AD. Neuro-
inflammation is a well-characterised feature of neurodegener-
ative events; its relevance has been highlighted through genet-
ic mutations associated with receptors of the innate immune
system and AD risk [32, 33]. Additionally, numerous studies
report alterations in astrocytic markers such as GFAP [34, 35]
and aquaporin 4 (AQP4) [36], as well as microglial markers
[15] in AD states.
Given the complex nature and likely interdependence of
the above-mentioned pathways, it is vital to understand how
they are initially activated and spread throughout the brain.
Equally, it is critical to determine primary vs. secondary
events via an analysis of associations with the established
spatio-temporal progression of principal hallmarks. Synaptic
loss, the UPR and neuro-inflammation have each been impli-
cated as early occurring cascades, evident in key brain regions
foremost affected at the initial stages of the disease (for exam-
ple, see [26, 37, 38]). Conceptually, the activation of such
cascades in regions affected at later stages, prior to the emer-
gence of regional Aβ and tau pathology, would support a
causative role in the spread of the disease, whilst later stage
detection following robust pathology would support a more
reactive downstream role for these stressors.
Here, we utilise a post-mortem tissue cohort of non-
diseased and AD cases, previously characterised for a variety
of tau and Aβ species [2, 3], to contextualise the activation of
the UPR and neuro-inflammation as well as associations with
synaptic loss within the lateral temporal cortex. Indicative
markers were determined according to diagnosis, pathological
severity and neuropathological staging. Additional correlative
analyses were performed with established Aβ and tau markers
as well as cognitive assessment scores.
Materials and Methods
Post-mortem Human Brain Samples
Human temporal cortex samples (middle temporal gyrus,
Brodmann’s area 21) were obtained from the Brains for
Dementia (BDR) consortium and sourced from the MRC
London Neurodegenerative Diseases Brain Bank, the
Thomas Willis Oxford Brain Collection, the Manchester
Brain Bank, the Newcastle Brain Tissue Resource and the
South West Dementia Brain Bank. Prior to patient death, in-
formed consent was attained. All procedures were approved
by the UK Medical Research Council.
Samples were received as either 500-mg frozen blocks (n =
46) or 5-μm-thick paraffin-embedded sections (n = 28) for
western blot or immunohistochemical analysis, respectively.
Cases were deemed as non-AD or AD, determined by clinical
and neuropathological assessment, as per medical history and
neuropathological assessments received by the BDR.
Corresponding biographical data including sex, age at death,
post-mortem interval (PMI), cortical pH, Braak staging,
CERAD neuritic plaque score, National Institute on Aging
and Alzheimer’s Association (NIA-AA) guidelines reporting
none, low, intermediate (Inter) or high neuropathic changes
related to AD and cognitive scores (Mini Mental State
Examination (MMSE); Clinical Dementia Rating (CDR)
global, memory and sum of box) were also supplied where
detailed. No significant differences in PMI or age were detect-
ed across analytical groups (see Table 1 for details and
Table S1 for additional information relating to Thal phase,
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the assessment of primary age-related tauopathy (PART; as
per guidelines in Crary et al. [39]) and apolipoprotein Ɛ4 allele
status of cases used).
Brain Lysate Preparation
Frozen tissue (100 mg) was manually homogenised in ~ 1:10
(w/v) Igepal/NP-40 (Sigma, Dorset, UK)-based lysis buffer
(in mM: 20 HEPES, 150 NaCl, 1% Igepal/NP-40, 0.1
EDTA, pH = 7.6) including protease and phosphatase inhibi-
tors (cOmplete mini and PhosStop, Roche Life Science,
Burgess Hill, UK). Homogenates were centrifuged (13,000g,
4 °C, 20 min) and supernatants containing soluble material
were stored at − 80 °C.
Western Blotting
Generated soluble lysates from each case were probed for
markers of synaptic integrity (postsynaptic density 95 (PSD-
95), Abcam—cat. # ab18258 and synaptophysin, Abcam—
cat. # ab32127), ER stress (binding immunoglobulin protein,
BiP), Abclonal—cat. # A0241; p-PERK, Cell Signalling—
cat. # 3179s; PERK, Cell Signalling—cat. # 3192s; p-eIF2α,
Cell Signalling—cat. # 9721s; eIF2α, Cell Signalling—cat. #
9722s; p-IRE1α, ThermoFisher—cat. # PA1-16927 and
IRE1α, Cell Signalling—cat. # 3294s) and neuro-
inflammation (GFAP, Sigma—cat. # G3893 and Iba1 cat. #
016-20001) (see Table S2 for further details).
Samples were subject to standard western blot protocols as
described previously [3]. Protein concentration was deter-
mined through bicinchoninic acid assay (BCA, Sigma) and
samples adjusted to the desired concentration in lithium dode-
cyl sulphate (LDS, Thermo Fisher, Paisley, UK) and 15 mM
dithiothreitol (DTT, Sigma). Samples were heated (70 °C,
10 min) and separa ted on 4–12% Bis-Tr is ge ls
(ThermoFisher) in either MOPS or MES SDS running buffer
(ThermoFisher). Proteins were transferred onto 0.2 μm or
0.45 μm nitrocellulose membranes via standard wet transfer
conditions. Membranes were washed in 0.05% Tween-20
(Sigma) containing Tris-buffered saline (TBST; in mM: 50
Trizma base, 150 NaCl, pH = 7.6), before blocking for 1 h at
room temperature in TBST containing 5% milk powder.
Primary antibodies were incubated overnight (4 °C) in
TBST containing 5% bovine serum albumin (BSA).
Appropriate secondary antibodies were applied for 1 h at
room temperature (goat anti-rabbit/goat anti-mouse, IgG,
HRP conjugated; Merck Millipore (1:5000)) prior to visuali-
sation using enhanced chemiluminescence (1.25 mM luminol,
30 μM coumaric acid, 0.015% H2O2). Membranes were
washed in TBST (3 × 5 min) between each stage of the proto-
col. Immunoreactivity was captured using a Vilber-Fusion-SL
camera (Vilber, Eberhardzell, Germany) at 16-bit for analysis
and 8-bit for illustration. Membranes were then re-probed for
total protein in the case of phospho-markers, as above, or
stained for total protein using Coomassie total protein stain
Table 1 Biographical information of the study cohort. Number of cases,
CERAD score, NIA-AA classification (none, low, intermediate (Inter)
and high degree of AD-related neuropathological change), sex (% male),
age at death, post-mortem interval (PMI) and cortical pH are indicated,
stratified according to diagnosis, neuropathological severity and individ-
ual Braak stage. Mean values presented alongside ± SEM
No.
cases
CERAD NIAA Male
(%)
Age range
(years)
Mean age
(years)
PMI range
(h)
Mean PMI
(h)
pH
range
Mean
pH
Diagnosis (Braak stage)
Non-AD (0–3) 27 C0-C2 None–Inter 44.4 74–103 86 ± 1.4 11–110 44.9 ± 5.2 5.4–6.9 6.3 ± 0.1
AD (4–6) 19 C2-C3 Inter–High 60 71–90 83.4 ± 1.2 20–87 46.6 ± 4.9 6–6.9 6.3 ± 0.1
Severity (Braak stage)
Low (0–2) 18 C0-C1 None–Low 66.7 74–103 85.3 ± 1.9 11–92 40.7 ± 6.2 6–6.7 6.3 ± 0.1
Moderate (3–4) 14 C0-C3 None–Inter 28.6 77–95 85.9 ± 1.5 13.5–101 51.5 ± 7 5.4–6.9 6.2 ± 0.2
Severe (5–6) 14 C1-C3 Inter–High 71.4 71–90 83.6 ± 1.5 20–78 46 ± 5.7 6.1–6.9 6.4 ± 0.1
Braak stage
0 3 C0 None 100 74–78 76.7 ± 1.3 11–56 30 ± 13.5 6–6.1 6.1 ± 0.1
2 15 C0-C1 None–Low 40 74–103 87 ± 2 12–92 42.8 ± 7 6–6.7 6.3 ± 0.1
3 9 C0-C2 None–Inter 33.3 78–95 87.6 ± 1.7 13.5–101 53.4 ± 9.5 5.4–6.9 6.2 ± 0.3
4 5 C2-C3 Inter 40 77–88 82.8 ± 2.2 26–87 48.2 ± 10.6 6.0–6.8 6.2 ± 0.2
5 6 C1-C3 Inter–High 83.3 82–88 83.8 ± 1.2 22–78 50.5 ± 10.1 6.1–6.6 6.3 ± 0.1
6 8 C3 Inter—High 50 71–90 83.5 ± 2.4 20–69 42.6 ± 6.9 6.3–6.9 6.5 ± 0.1
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(see Fig. S1 for example of Coomassie-stained membranes) as
previously described [2, 3].
Supportive native state dot blots (as per [2, 3]) for AQP4
were conducted due to the incompatibility of the antibody
with western blotting protocols.
Immunohistochemistry
Fixed brain sections were de-waxed in xylene and rehydrated
in ethanol followed by a 20-min antigen retrieval treatment in
boiling citric acid solution (10 mM citric acid, 0.05% Tween-
20, pH = 6). After blocking for 1 h at room temperature in
phosphate-buffered saline (PBS; 0.01 M) containing 1.5%
normal goat serum, 1% milk powder, 2% BSA and 1% triton,
primary antibodies against GFAP (Alexa 488 conjugated,
1:500; Novus Biologicals, Abingdon, UK), Iba1 (1:200,
Wako) and AQP4 (1:100, Merck Millipore) were incubated
overnight at 4 °C. Additional sections with no primary anti-
body served as secondary antibody controls. Secondary anti-
bodies were applied (goat anti-rabbit Alexa 594, 1:500,
ThermoFisher) for 1 h at room temperature in PBS containing
2% BSA before mounting (Prolong® Diamond Antifade
Mountant with DAPI, ThermoFisher). Where appropriate,
sections were washed in PBS. Sections were viewed and cap-
tured (15 images per section; randomised fields independent
of grey or white matter) using an Axioskop 2 plus microscope
(Zeiss, Cambridge, UK) and Axiovision software. From the
28 cases for which histology sections were available, no fewer
than a total of 24 cases (1 section per case) were assessed for
each marker (for specifics of each marker, see relevant figure
legends).
Quantification and Cohort Stratification
Quantification was conducted using ImageJ (ver. 1.47, NIH,
USA) software. For western blot analysis, immunoreactivity
was quantified according to area under the curve (AUC) mea-
surements and adjusted to respective total protein markers (for
phospho-markers) or total protein Coomassie stain. Adjusted
values were subsequently normalised to control groups within
blots (according to classifications below) before all data for
each marker were pooled.
For immunohistological analysis, captured images were
quantified according to area stained (15 images per section
were averaged to give overall % area stained, and then data
was pooled as below). Equal exposure, background and
threshold settings were implemented. For all markers, cases
within the cohort were processed in batches, with comparisons
between runs made to ensure reproducibility. Thus, the quan-
tification of a marker represents pooled measures across mul-
tiple blotting/staining runs.
For all data, values were expressed relative to appropriate
controls and analysed according to the following three classi-
fications [2, 3]:
1) Clinical diagnosis of AD, confirmed post-mortem (non-
AD=Braak 0–3; AD =Braak 4–6)
2) Neuropathological phospho-tau severity, grouped as low
(Braak 0–2), moderate (Braak 3–4) or severe (Braak 5–6)
3) Individual Braak stages (normalised to Braak stage 2)
Additional analysis reporting the impact of overall AD rel-
evant neuropathological change was conducted following the
cohort stratification according to the National Institute of
Aging-Alzheimer’s Association guidelines (NIA-AA) as de-
termined by Braak neurofibrillary tangle staging, Thal phases
and CERAD scores [40]. Furthermore, the potential associa-
tion of each marker with APOE-related risk (as determined by
ε4ε4 = 2; ε3ε4 = 1; ε3ε3 = 0; ε2ε4 = 0; ε2ε3 = − 1; ε2ε2 = −
2 scoring) was also conducted.
Statistical Analysis
Statistical analysis was conducted using Graphpad Prism 5
software. Normal distribution was probed via a Shapiro-
Wilk test. Comparisons of two data sets were conducted using
Student’s two-tailed t test, with Welsh correction if appropri-
ate, or Mann-Whitney test for non-parametric data. A one-
way analysis of variance (ANOVA) or Kruskal-Wallis test
was conducted for multiple group analysis. Where statistical
significance was indicated, Bonferroni or Dunn’s post hoc
tests were implemented. Spearman’s rank correlation coeffi-
cient (r) was used to determine correlations and probable error
(P.E.) of coefficient was calculated for each significant corre-
lation. For all data, the level of significance was set as
p < 0.05.
Results
Synaptic Pathology
Synaptic loss and its associations with AD pathology and
progression was first determined via immunoblotting of the
postsynaptic marker, PSD-95 and the presynaptic marker,
synaptophysin. For clinically and neuropathologically diag-
nosed AD cases, reduced levels of PSD-95 were confirmed
(Fig. 1a(i, ii), p < 0.05). PSD-95 levels also declined with dis-
ease severity (Fig. 1a(iii), p < 0.05), without significant
change between the 3 severity classifications, yet in agreement
with Braak stages (Fig. 1a(iv), p < 0.05, r = 0.33, P.E. ± 0.14).
Together, our results confirmed the progressive loss of this
postsynaptic marker for all group stratifications.
3261Mol Neurobiol  (2020) 57:3258–3272
In contrast, the presynaptic marker synaptophysin was un-
changed across diagnosis (Fig. 1b(i, ii)) and individual Braak
stage (Fig. 1b(iv)), although a strong trend emerged when
analysed across disease severity (Fig. 1b(iii), p = 0.058). This
suggests that the presynaptic compartment is overall less affect-
ed in AD, and only marginally so in comparison to its postsyn-
aptic counterpart. Interestingly, however, when samples with
additional pathologies not directly related to ADwere excluded
(n = 5; see Table S1 for cases excluded), a significant reduction
in synaptophysin levels was detected (non-AD vs. AD
(p < 0.05); Braak stage (p < 0.05, r = − 0.36, P.E. = ± 0.15);
see Fig. S2), indicating a possible impact of secondary pathol-
ogies on the presynaptic compartment. For all other markers
analysed, exclusion of additional pathologies yielded no
marked changes in statistical outcomes.
Surprisingly, correlative analysis between synaptic pathology,
cognitive scores and other AD-related pathology markers [2, 3]
revealed that neither synaptic marker correlated with CERAD
(neuritic plaque) or cognitive scores from multiple assessments
(p > 0.05 for all). Furthermore, neither marker correlated with
Aβ pathology, but both demonstrated some degree of correlation
with tau, specifically phospho-tau, measures (Table 2).
UPR Pathology
To explore the proposed link between ER stress and AD, we
next analysed levels of the ER chaperone protein, BiP, and
UPR markers p-PERK, p-eIF2α and p-IRE1α. No changes in
BiP were detected across AD cases compared to non-AD
cases (Fig. 2a(i, ii)), or when analysed according to disease
severity (Fig. 2a(iii)). Phosphorylated proteins (relative to to-
tal) yielded a significant increase for p-PERK in AD cases
compared to non-AD controls (Fig. 2b(i, ii), p < 0.05), which
could be attributed to an elevation between low and severe
Fig. 1 Postsynaptic markers decrease with AD progression. i)
Representative images of western blots probed for a PSD-95 and b
synaptophysin with molecular weights and diagnosis of non-AD (con-
trols, (C)) and AD (A) indicated. An area of each blot stained for total
protein loading is additionally shown as means of a loading control.
Quantified markers were stratified according to ii) diagnosis, iii) disease
severity (low, Braak 0–2; moderate, Braak 3–4; severe, Braak 5–6) and
iv) individual Braak stage for Spearman’s rank correlation (r) analysis.
Significant post hoc inter-group differences are indicated (*). Data for
PSD-95 (n = 45) and synaptophysin (n = 46) are provided as scatter plots
with means with 95% confidence intervals, *p < 0.05
Table 2 Correlations between synaptic markers with β-amyloid and tau pathology. Spearman’s rank correlations (r) between synaptic, amyloid-
β (Aβ) and tau markers are reported. Negative correlations are indicated by arrows. *p < 0.05, **p < 0.01, $trend. N.S. not significant
Marker Soluble Aβ Fibrillar Aβ Oligomeric tau Phosphorylated tau Total tau
MOAB OC TOC-1 PHF-1 AT-8 CP-13 HT-7
PSD-95 N.S. N.S. N.S. *r = 0.33 ± 0.14 (↓) *r = 0.3 ± 0.14 (↓) N.S. N.S.
Synaptophysin N.S. N.S. N.S. N.S. $p = 0.07 (↓) N.S. N.S.
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disease stages (Fig. 2b; Braak ≤2 vs. Braak 5–6, p < 0.05).
Somewhat unexpectedly, this finding was not matched by p-
eIF2α levels, a direct downstream target of p-PERK. Instead,
phosphorylation levels of this protein remained unaffected for
diagnosis status (Fig. 2c(i, ii)) and disease severity (Fig.
2c(iii)). Similarly, no changes in p-IRE1α expression
emerged for any analysed parameter (Fig. 2d(i–iii)).
Analysis of total PERK, eIF2α and IRE1α levels also report-
ed no change (see Fig. S3). Taken together, these data show
that only p-PERK is altered over the course of AD, and par-
ticularly in late AD stages, largely inconsistent with the coor-
dinated activation of the UPR.
Analysis of UPR markers with cognitive scores and neuro-
pathological staging found that only p-PERK, in line with our
Fig. 2 Selective elevation of UPRmarkers with end-stage AD pathology.
i) Representative images of western blots probed for a BiP, b p-PERK/
PERK, c p-eIF2α/eIF2α and d p-IRE1α/IRE1α. Molecular weights and
diagnosis of non-AD (C) and AD (A) are indicated, alongside images of
Coomassie total protein stain as loading controls. Markers were quanti-
fied according to ii) diagnosis and iii) disease severity (low, 0–2;
moderate, Braak 3–4; severe, Braak 5–6). Significant post hoc inter-
group differences are indicated (*). For all phosphorylated markers, scat-
ter plots are shown as phospho-signal adjusted for total relative to appro-
priate controls. BiP (n = 45), p-PERK (n = 37), p-eIF2α (n = 45), p-
IRE1α (n = 23) data displayed as scatter plots with means with 95%
confidence intervals, *p < 0.05
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previous data, displayed any degree of correlation. This associ-
ated well with Braak staging (p< 0.05, r= 0.42, P.E. = ± 0.16)
and CDRmemory assessment (p < 0.05, r = 0.34, P.E. = ± 0.16),
as well as yielding a strong trend with CERAD and CDR global
scores (p = 0.061 and p = 0.059, respectively). Moreover, p-
PERK correlated with phospho-tau markers. Interestingly, levels
of total eIF2α displayed strong negative correlative trends with
tau pathology (Table 3).
Neuro-inflammation
Neuro-inflammation, associated with activated astrocytes and
microglia, was next probed alongside AD criteria. Surprisingly,
we found no difference in the expression of the microglial mark-
er, Iba1, across all analysed parameters (Fig. 3a(i–iv)).
Conversely, the astrocytic marker, GFAP, demonstrated a signif-
icant elevation in accordance with AD diagnosis (Fig. 3b(i, ii),
p < 0.01), and AD pathological severity (Fig. 3b(iii), p < 0.01).
We further established that this increase was primarily due to an
upregulation in severe AD cases (Braak ≤ 2 vs. Braak 5–6,
p < 0.05; Braak 3–4 vs. Braak 5–6, p < 0.05), suggesting that
astrocytic upregulation is a late-stage event. Not unexpectedly,
GFAP was subsequently found to correlate well with Braak
(neurofibrillary tangle) staging (Fig. 3b(iv); r= 0.41, p < 0.01).
In line with these findings, correlation analysis revealed
that Iba1 did not associate with any measures of cognitive
decline or hallmark AD pathology (all p > 0.05). GFAP, on
the other hand, yielded weak to moderate correlations for neu-
ropathological staging (CERAD, r = 0.44, P.E. = ± 0.14,
p < 0.05) and measures of cognitive assessment (MMSE
(r = − 0.39, P.E. = ± 0.15), CDR SOB (r = 0.43, P.E. = ±
0.14), p < 0.05; CDR global (r = 0.4, P.E. = ±0.14) and mem-
ory (r = 0.46, P.E. = ± 0.14), p < 0.01). Additionally, GFAP
correlated well with both Aβ and tau measures (Table 4).
To further explore whether neuro-inflammation and specifi-
cally astrocyte activation emerge in later stages of the disease
process , we car r ied out addi t ional quant i ta t ive
immunohistochemical analysis on a subset of AD cases (see
Table S1 for cases used). Again, Iba1 immunostaining levels
remained consistent across all Braak stages analysed (Fig. 4a)
and reactivity was found unchanged in both diagnosed AD cases
(Fig. 4d) and across disease severity (Fig. 4e). In contrast, GFAP
staining across all Braak stages indicated an associated rise in
astrogliosis. Little staining was detected in Braak 0–2, increasing
in Braak 3–4 cases, and abundant in late stages 5–6 (Fig. 4b).
Accordingly, GFAP levels were significantly increased across
disease severity, particularly in severe AD cases (Fig. 4g).
GFAP levels were not consistently upregulated across diagnosis
status (Fig. 4f); however, this is likely due to higher variability
within the AD group and the reduced number of respective cases
analysed (n = 9). We also examined expression levels of the
water channel AQP4, located on astrocytic end feet, which has
been implicated in AD pathology due to its role in Aβ clearance
[38]. No differences in AQP4 stainingwas seen across anyBraak
stages (Fig. 4c) and levels remained unchanged in diagnosedAD
cases (Fig. 4h) and across severity (Fig. 4i). The unalterated
status of AQP4 as part of AD pathology in the lateral temporal
cortex was further supported by native state dot-blot measure-
ments in a subset of cases, in which immunoreactivity was com-
parable between groups in all analytical parameters (see Fig. S4).
Impact of Cohort Stratification and Co-variants
Given the potential influence of cohort stratification to alter the
above statistical outcomes, the entire data set presented here was
reanalysed following alternative stratification according to the
NIA-AA guidelines reflecting the degree of AD-related neuro-
pathological change. Consistently, analysis with non-parametric
Kruskal-Wallis tests as well as Spearman’s rank correlations
demonstrated largely the same outcome when classified under
NIA-AA guidelines as to when grouped according to Braak
stages (see Table S3). Aside from supportive correlations of
p-PERK (p < 0.05, r = 0.39, P.E. = ± 0.16) and GFAP
(p < 0.05, r = 0.35, P.E. = 0.15) with Thal phase, no further
Table 3 Correlations of UPR markers with β-amyloid and tau pathology. Spearman’s rank correlations (r) of UPR markers with amyloid-β (Aβ) and
tau pathology are illustrated. Negative correlations specified (↓). *p < 0.05, **p < 0.01, $approaching significance. N.S. not significant
Marker Soluble Aβ Fibrillar Aβ Oligomeric tau Phosphorylated tau Total tau
MOAB OC TOC-1 PHF-1 AT-8 CP-13 HT-7
p-PERK N.S. N.S. N.S. $p = 0.053 *r = 0.37 ± 0.14 *r = 0.41 ± 0.14 N.S.
PERK N.S. N.S. N.S. N.S. N.S. N.S. N.S.
p-eIF2α N.S. N.S. N.S. N.S. N.S. N.S. N.S.
eIF2α N.S. N.S. $p = 0.073 (↓) $p = 0.06 (↓) $p = 0.052 (↓) N.S. N.S.
p-IRE1α N.S. N.S. N.S. N.S. N.S. N.S. N.S.
IRE1α N.S. N.S. N.S. N.S. N.S. N.S. N.S.
BiP N.S. N.S. $p = 0.072 N.S. N.S. N.S. N.S.
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significant effect nor correlation with, Thal phase, APOE allele
status or PART classification was reported for any marker
analysed here. Similarly, no correlation was found with age or
PMI for any measure.
Discussion
This study sought to build on a previously well-characterised
AD cohort [2, 3], quantifying and contextualising synaptic
loss, ER stress and neuro-inflammatory pathology in the tem-
poral lobe of post-mortem human AD tissue. Data were ex-
amined across neuropathological and cognitive scores and
revealed that key candidates emerged late in the temporal
cortex, more robustly associated with tau rather than Aβ pa-
thology, and selectively correlated with cognitive decline.
Synaptic Pathology
Synaptic dysfunction and loss is a defining feature of AD and is
recognised as the best correlate of cognitive impairment [17,
41]. In line with previous reports [34, 42, 43], this study dem-
onstrates a significant decrease in the expression of the postsyn-
aptic protein, PSD-95, in AD cases. Interestingly, we observed
no reduction in levels of the presynaptic marker, synaptophysin
[43–45] or the reported early decrease in synaptic proteins,
typically observed within the hippocampus or frontal cortex
[16, 18, 37]. We must note that our employed method of inves-
tigating total expression levels is not a direct measure of func-
tional synapses. Critically, however, we suggest that the differ-
ential outcome may largely depend on (1) The region investi-
gated and (2) the composition of the study cohort.
Indeed, synaptic loss within the hippocampus [18, 19, 46]
and the frontal cortex [17, 41, 47, 48] are frequently reported
Fig. 3 Astrocytic expression increases with end-stage AD pathology, but
microglial expression remains unchanged. i) Example western blots
stained for a Iba1 and b GFAP expression with molecular weights and
individual diagnosis (non-AD (C), AD (A)) illustrated. Coomassie total
protein loading controls are also shown. Stratified quantification of
markers according to ii) diagnosis, iii) severity (low, Braak 0–2;
moderate, Braak 3–4; severe, Braak 5–6) and individual Braak stages
for correlation analysis (Spearman’s rank correlation (r)). Significant post
hoc inter-group differences are indicated (*). Data for Iba1 (n = 46),
GFAP (n = 46) given as scatter plots with mean values with 95% confi-
dence intervals, *p < 0.05 and **p < 0.01
Table 4 Correlations of inflammatory markers with β-amyloid and tau pathology. Spearman’s rank correlations (r) of amyloid-β (Aβ) and tau
pathology with Iba1 and GFAP are illustrated. *p < 0.05, **p < 0.01, **p < 0.001, $approaching significance. N.S. not significant
Marker Soluble Aβ Fibrillar Aβ Oligomeric tau Phosphorylated tau Total tau
MOAB OC TOC-1 PHF-1 AT-8 CP-13 HT-7
Iba1 N.S. N.S. N.S. N.S. N.S. N.S. N.S.
GFAP $p = 0.062 ***r = 0.51 ± 0.13 *r = 0.34 ± 0.15 **r = 0.38 ± 0.14 ***r = 0.48 ± 0.14 *r = 0.35 ± 0.14 **r = 0.53 ± 0.13
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as early and correlative with cognitive decline. Yet, several
post-mortem studies have highlighted a disconnect between
these early affected regions and those observed elsewhere. For
instance, the earliest synaptic loss may be confined to the
hippocampus [19], and while frontal cortical synaptic loss
may reflect global cognitive impairment, measures in the same
cases revealed that superior temporal cortical loss may not
[41]. Frontal lobe synaptic loss does also not correlate with
decrease in the temporal lobes (reviewed in [49]). In line with
our present findings, studies investigating the temporal lobe
also reported synaptic decline in the more advanced pathology
stages for most markers [44]. Particularly within the temporal
lobes, postsynaptic dysfunction may indeed be more promi-
nent, with reports of a post-synaptic drebrin decline earlier
[44] or in the absence [50] of a synaptophysin decrease.
Somewhat independent of region, we note that studies
which have clearly defined, low Braak stage (0–1) controls
[37, 42], or those which limited their cohort to the extremes of
pathology, more readily report robust synaptic loss [45]. This
is in contrast to here and elsewhere [44], where a broader
range of cases were analysed, mostly corroborating a later
change in synaptic integrity. Such dependence on analytical
strategy is typified by Mukaetova-Ladinska et al. [51] where
statistically relevant differences were observed dependent on
cohort grouping, ultimately leading the authors to report syn-
aptic loss as a late occurrence. Interestingly, when analysed
across individual Braak stages, an initial increase in synaptic
markers was also reported, prior to a later decline, akin to the
subtle increase in both PSD-95 and synaptophysin observed
here within moderate cases. Such an initial upregulation of
synaptic markers may be indicative of synaptic compensatory
mechanisms, as suggested by others [52–55].
In the present cohort, modest associations with tau pathol-
ogy but no correlation with Aβ pathology or CERAD neuro-
pathological assessment were seen with PSD-95 levels. It
must, however, be noted that the potential biphasic response
in synaptic markers likely weakens such linear correlations.
Nevertheless, the lack of association seen with Aβ is at odds
with synaptotoxicity studies of this peptide [4, 56, 57], espe-
cially those which demonstrate a loss of PSD-95 following the
local application of Aβ oligomers [58]. The synaptotoxicity of
tau is less studied, yet, knock-in or overexpression of FTLD
mutant human tau in mice is reported to reduce synaptic trans-
mission and efficacy [59, 60] and several studies have indicat-
ed that Aβ-mediated synaptic impairment is in fact dependent
on phospho-tau [61, 62].
Perhaps the most striking was the finding that neither syn-
aptic marker correlated with any measures of cognitive decline.
Fig. 4 Immunohistochemical analysis confirmed end-stage upregulation
of astrocytic expression. Representative images (magnification × 40,
scale bar = 50 μm) of fixed brain sections of the lateral temporal cortex
stained for a Iba1, bGFAP and cAQP4with cases determined as i) Braak
(Br) stage 0–2, ii) Br 3–4 and iii) Br 5–6 shown. Markers quantified as %
area stained and stratified according to d, f, h diagnosis and e, g, i disease
severity (low, Braak 0–2; moderate, Braak 3–4; severe, Braak 5–6).
Significant post hoc inter-group differences are indicated (*).
Quantification of Iba1 (n = 24), GFAP (n = 24), AQP4 (n = 26), reported
as scatter plots with means with 95% confidence intervals, *p < 0.05
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However, with the aforementioned disruptive nature of a bi-
phasic synaptic response to linear correlation, and possible
compensatory upregulation, it is plausible that the predictive
value of cognitive decline associated with regional synaptic loss
may not be homogenous throughout the brain [41].
It is interesting to note that removal of cases noted to have
additional non-AD-related pathologies from our data set
yielded different statistical outcomes, potentially suggesting
that at least in the lateral temporal lobe, synaptic number
and/or composition may be commonly affected by a variety
of stressors. The individual differences with the cohort affect-
ed by co-morbidities may havemasked a stronger contribution
of Aβ and tau to synaptic dysfunction and its consequential
impact on cognition. This reaffirms the necessity of detailed
record keeping and considerations of comorbid confounders
for quantitative pathological measures.
Collectively, current data suggest that robust synaptic loss
in the lateral temporal lobe is a later-occurring event in the
pathology of AD.Within this region, AD-driven synaptic dys-
regulation preferentially affects the postsynaptic compartment
and is closely associated with the accumulation of pathologi-
cal tau over Aβ species.
ER Stress
We here also detected activation of the UPR in AD cases,
although this appeared to be selective for p-PERK levels, which
correlated with Braak stages, NIA-AA classifications, Thal
phase and some measures of cognitive decline. The elevation
of p-PERK was without a corresponding increase in p-eIF2α,
the downstream substrate. Such observations are in line with
the study of Bruch and colleagues where an increased p-PERK
was reported alongside suppressed total eIF2a levels [63].
Previous studies in AD cases have observed increased UPR
markers, e.g. pre-tangle phospho-tau bearing neurons of the
hippocampus expressed elevated levels of p-PERK and p-
eIF2α [20, 22, 26]. Similar findings have also been reported
in several tauopathy variants [27]. More recent work by
Duran-Aniotz and colleagues reported an elevation of p-
IRE1α in the hippocampus of AD cases, in close association
with Braak staging [21]. This close association with pre-tangle
pathology has led to the notion that the UPR is activated early
in the course of the disease and may contribute to disease
pathogenesis. Here, associations of p-PERKwith pathological
tau markers were also established, but elevated levels were
confined to late-stage pathological cases and occurred without
the corroborative changes in other key markers. The delayed
activation of the UPR over the course of AD within the neo-
cortical regions is further supported by similar findings within
the frontal cortex, in which p-PERK was selectively elevated
in Braak stage 6 cases, in the absence of enhanced p-eIF2α
levels [64]. Equally, quantification of p-PERK immunostain-
ing in AD cases has revealed a more modest activation within
the frontal cortex as compared to the hippocampus within the
same cases [22]. Nevertheless, certain cortical areas may be
more susceptible to ER stress than others, given the regional
specificity in which BiP is found elevated [65].
It must also be considered that many of the studies
reporting early, multi-marker activation of the UPR did so
through immunohistological detection [20–22, 26], in contrast
to immunoblot-based studies (here and, e.g. [64]), which typ-
ically report later, incomplete activation. Only some sub-
populations of neurons within each region are likely to expe-
rience a degree of ER stress sufficient to activate the UPR and,
consequently, more global assessments via immunoblot may
mask selective differences. Thus, immunoblot techniques are
able to establish changes in severe stages of disease when
pathology is substantial, while immunohistochemical tech-
niques likely provide a better resolution regarding cell type-
and region-specific changes.
Independent of the method of detection, and consistent
with our findings, post-mortem studies have invariably found
a close association of the UPRwith tau pathology [20–22, 26].
Such a specific association is surprising given that in addition
to tau [24], both Aβ oligomers [66] and BACE1 products [67]
have been demonstrated to induce the UPR. Furthermore, in
AD models, the UPR is linked to the promotion of Aβ pro-
duction via enhanced BACE1 expression [25, 68] and dimin-
ished APP turnover [21]. Nevertheless, here we found no ev-
idence of enhanced p-eIF2α levels and likewise, we are un-
able to support the association of reduced protein synthesis,
via p-eIF2α, with synaptic failure and memory deficits which
has been reported in animal models [23, 28, 29, 63]. As for all
human tissue studies, the impact of post-mortem interval
(PMI) on phosphorylated protein levels must be considered
[69, 70].
Given that in this cohort we have previously observed sig-
nificant tau and Aβ pathology within intermediate Braak
stages [2, 3], our data illustrate that specific UPR markers
track disease pathology late in the disease course and, thus,
may be reactive to pathology in the temporal lobe rather than
facilitatory of pathological spread. Nevertheless, UPR activa-
tion may further exacerbate degenerative disease processes.
Neuro-inflammation
Similar to synaptic loss, neuro-inflammation is a characteristic
feature of AD. In line with this and previous findings, we
confirmed a significant upregulation of GFAP in AD cases
compared to controls [34, 35, 71], particularly in severe
(Braak stage 5–6) AD cases [71]. We extended on these prior
reports, establishing the robust upregulation of GFAP within
the AD temporal lobe as restricted to late-stage AD cases. This
is somewhat in contrast to reports of a biphasic response in
MCI and AD patients as measured by the monoamine oxidase
B inhibitor PET ligand (11C-deuterium-L-deprenyl; DED),
3267Mol Neurobiol  (2020) 57:3258–3272
which is supportive of an early upregulation and later decline
of astrogliosis [38, 72]. However, such reports have indicated
that these early changes are region specific, observing alter-
ations in DED retention times only in the frontal and parietal
cortex [38]. Furthermore, a disconnect between DED reten-
tion and GFAP staining in an FAD mouse model has raised
concerns over the specificity of the ligand [73], suggesting
that at present, there is no clear evidence for an early inflam-
matory (astroglia) reaction in human AD [74]. Nevertheless,
several cross-sectional AD animal model studies found an
early upregulation of astrocytes, preceding Aβ plaque depo-
sition and correlative with soluble Aβ [73, 75, 76].
Here, we observed GFAP correlations with neuropatholog-
ical Braak stage, CERAD, NIA-AA and Thal phase assess-
ment scores as well as phospho-tau and Aβ. This may be
associated with a late-stage inflammation as a result of astro-
cyte accumulation around Aβ species [77], although others
[78] focussing on the temporal cortex, also observed greater
correlative strength between pathological tau vs. Aβ patholo-
gy. Given astrogliosis is evident in response to numerous neu-
rodegenerative insults (reviewed by Ransohoff [79]), the prin-
cipal driving force for their activation may largely vary de-
pending on the extent of regional pathology.
Strikingly, we observed a modest but significant corre-
lation between GFAP levels and all measures of cognitive
decline. This was somewhat unexpected, considering the
lack of a corresponding relationship with synaptic mea-
sures. Nevertheless, substantial evidence supports the un-
derpinning of cognition via astrocytic facilitation of syn-
aptic signalling and plasticity, and its subsequent disrup-
tion during pathology [80]. Accordingly, the inhibition of
excessive astrocytic signalling may protect against cogni-
tive decline, independent of Aβ, as shown in a FAD
mouse model [81]. Collectively, out of all markers inves-
tigated, GFAP correlated best with both Aβ and tau pa-
thology as well as cognitive deficits, suggesting that as-
trocytes track both disease progression and pathology.
However, as elevations of GFAP emerged after tau and
Aβ , astrogliosis appears to be reactive to initial
pathology.
Despite the fact that GFAP and thus astrogliosis can be
considered a robust indicator of the disease, we failed to
observe any significant overt change in the water channel
AQP4, thought to be involved in the glymphatic clearance
of Aβ [82, 83] and proposed to be disrupted in AD [36].
Nevertheless, our measurements of AQP4 were either
sampled at random within the temporal lobe via histology
or represented total tissue levels in immunoblots and thus
were not localised to the site of plaques, where greatest
changes have been identified [84, 85]. We similarly de-
tected no changes in the expression levels for Iba1, a
general marker of microglia. Indeed, notwithstanding the
well-documented activation of microglia in AD [15], a
recent systematic review of microglial markers in post-
mortem human AD tissue reported that half of the publi-
cations quantifying Iba1 levels detected no change in ex-
pression compared to controls. Interestingly, these hetero-
geneous results based on Iba1 labelling of all microglia
were not seen with a marker specific to activated microg-
lia, CD68, which was consistently elevated in AD cases
[86]. In line with this, it has been proposed that increased
activation as opposed to proliferation of microglia occurs
in AD [86, 87]. As a result, future work will be required
to evaluate the context of microglial responses in relation
to AD pathologies.
Concluding Remarks
In summary, our data suggest that specific synaptic, ER
stress and neuro-inflammatory markers are affected in late
AD in the temporal gyrus. This study does not rule out
dysregulation earlier elsewhere in the brain or the differ-
ential effect on specific neuronal subtypes. However, giv-
en that our previous analysis of temporal cortical tau and
Aβ pathology within the same cohort has demonstrated
the co-localisation of soluble Aβ and tau pathology at
intermediate stages of neuropathological severity (Braak
NFT stages 2–3), the pathways studied here do not pre-
cede the spread of tau or Aβ pathology and are likely
secondary events. Strong associations of affected mea-
sures were detected with phospho-tau species, and less
so with Aβ pathology, thus being at odds with the as-
sumption that the Aβ cascade primarily drives disease
processes. Though we cannot rule out the contributions
of ER stress and neuro-inflammation to the initial emer-
gence of tau and Aβ pathology at the site of origin (e.g.
EC/hippocampus for tau [6], orbitofrontal cortex and in-
ferior temporal gyrus for Aβ [8, 9], or early synaptic loss
within these regions), our data suggest that neither of
these pathways precedes the pathology in the middle tem-
poral gyrus. Sequential progression of pathology through-
out the brain, distinct from pathogenesis, may be more
dependent on the associated biochemical properties of
protein seeding as suggested by a prion-like spread [88].
Nevertheless, the ensuing activation of detrimental degen-
erative cascades likely exacerbates the overall degenera-
tion. Consequently, therapeutic targeting of the underly-
ing mechanisms may not halt the disease, yet may serve
to ameliorate and thus delay further cellular dysfunction
throughout the disease course.
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